Skip to main content

Roche lifts full-year outlook after H1 sales rise 18%

Swiss drugmaker Roche lifted its full-year sales outlook after revenue in the first half rose 18 percent, helped by newer drugs including multiple sclerosis medicine Ocrevus and cancer immunotherapy Tecentriq.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.